These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19434004)

  • 1. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
    Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Eustace AJ; Crown J; Clynes M; O'Donovan N
    J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
    Vojvodic M; Hansford LM; Morozova O; Blakely KM; Taylor P; Fathers KE; Moffat J; Marra M; Smith KM; Moran MF; Kaplan DR
    Curr Drug Discov Technol; 2013 Dec; 10(4):283-304. PubMed ID: 23701117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on dual Src/Abl inhibitors.
    Musumeci F; Schenone S; Brullo C; Botta M
    Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
    Tarpley M; Abdissa TT; Johnson GL; Scott JE
    Anticancer Res; 2014 Apr; 34(4):1629-35. PubMed ID: 24692691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies of dasatinib, its targets and predictors of sensitivity.
    Jilaveanu LB; Zito CR; Aziz SA; Chakraborty A; Davies MA; Camp RL; Rimm DL; Dudek A; Sznol M; Kluger HM
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):386-9. PubMed ID: 21320292
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
    Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
    Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
    [No Abstract]   [Full Text] [Related]  

  • 13. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM; Saigal B; Tran H; Donato NJ
    Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src as a Therapeutic Target in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
    Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
    Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
    Dai Y; Chen S; Shah R; Pei XY; Wang L; Almenara JA; Kramer LB; Dent P; Grant S
    Blood; 2011 Feb; 117(6):1947-57. PubMed ID: 21148814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P; Zhang W; Gorlick R; Kolb EA
    Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
    Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
    Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.